Survey
Quarterly Survey: Depression Bipolar Disorder Treatments and AXSM's Auvelity and ITCI's Caplyta October 2023
Ticker(s): AXSM, ITCI, TAKThe survey includes 20 Psychiatrists.
Are you familiar with Auvelity (dextromethorphan HBr-bupropion HCl) and data to date?
Are you familiar with Caplyta (lumateperone) and data to date?
How would you best describe your practice?
How many patients with Major Depressive Disorder (MDD) do you have under your care?
How many MDD patients do you currently have on the following drugs:
- Trintellix:
- Auvelity:
- Generic Buproprion:
- Generic SSRI/SNRIs
- :Other:
What are your general thoughts on Auvelity and what role, if any, do you see Auvelity playing in your practice?Please be specific.
What percentage (%) of the patients that you have started on Auvelity so far have responded well and are expected to stay on the drug for at least 6 months? If no patients on Auvelity, please type 'NA'.
How would you rate the current ease of prescribing Auvelity versus Trintellix, and if it's currently challenging, do you anticipate a substantial improvement in prescription accessibility in the coming year? Please be specific.
To what extent, if any, are you prescribing the generic combination of buproprion and dextromethorphan in place of branded Auvelity in your practice? Please be specific.
What percentage (%) of your MDD Patients are adequately-controlled with their current drug regimen vs. inadequately controlled? Please indicate 0-100 for each, must sum to 100.
- Adequately controlled:
- Inadequately controlled:
Of the [X]% of patients that are inadequately controlled, what % of these patients do you expect to try Auvelity?
Approximately how many new MDD patients enter your practice over the course of a year?
And of those new MDD patients, what percentage (%) do you expect to try Auvelity (either immediately or after failing on another drug)?
How many patients total do you expect to have on Auvelity at the following points in time (please factor in both new patient starts and expected patient discontinuations):
- In 6 months:
- In 1 year:
- In 3 years:
What is your general view of Caplyta? What role, if any, do you see Caplyta playing in your practice? Please be specific.
How many patients do you have on Caplyta today?
How many patients did you start on Caplyta over the last 30 days?
How many patients discontinued Capltya over the last 30 days?
How many patients total do you expect to have on Caplyta at the following points in time (please factor in both new patient starts and expected patient discontinuations):
- In 6 months:
- In 1 year:
- In 3 years:
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
